Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Tranilast

Anti-inflammatory and anti-angiogenic
 
ALX-550-409-M010 10 mg 53.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-CT110

Anti-inflammatory and anti-angiogenic agent. Inhibits VEGF-induced angiogenesis in vivo . Inhibits proliferation and tube formation of human endothelial cells in vitro. Also inhibits smooth muscle cell proliferation and prevents post-angiplasty retsenosis.Synthetic compound with structural similarity to the tryptophan (Trp) catabolites kynurenines. Tranilast ameliorates the disease severity in animal models of multiple sclerosis, in part, by inducing T cell tolerance. Trp degradation is an important mechanism in the maintenance of T cell tolerance in a variety of disease models and is mediated by the rate limiting enzyme indoleamine 2,3-dioxygenase (IDO).

Product Specification

Alternative Name:N-(3’,4’-Dimethoxycinnamoyl)anthranilic acid, 3,4-DAA
 
Formula:C18H17NO5
 
MW:327.3
 
CAS:53902-12-8
 
MI:14: 9570
 
RTECS:DG8731000
 
Purity:≥95% (HPLC)
 
Appearance:Off-white to yellow solid.
 
Solubility:Soluble in DMSO.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Handling:Protect from light.
 
550-409
Please mouse over
550-409

Product Literature References

Tranilast: a pharmaceutical candidate for reduction of adhesions using a novel approach: J. Petrilli, et al.; Semin. Reprod. Med. 26, 341 (2008), Abstract;
Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key: M. Platten, et al.; Drug Discovery Today 3, 401 (2006), Abstract;
Tranilast: a novel weapon against insulin resistance: M.R. Namazi & J. Soma; Med. Hypotheses 64, 1135 (2005), Abstract;
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite: M. Platten, et al.; Science 310, 850 (2005), Abstract;
Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells: M. Spiecker, et al.; Mol. Pharmacol. 62, 856 (2002), Abstract; Full Text
Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells: A. Chikaraishi, et al.; Eur. J. Pharmacol. 427, 151 (2001), Abstract;
Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53: A. Takahashi et al.; Circ Res 84, 543 (1999), Abstract;
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo: M. Isaji et al.; Br. J. Pharmacol. 122, 1061 (1997), Abstract;
Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts: H. Yamada, et al.; J. Biochem. 116, 892 (1994), Abstract;
Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages: H. Suzawa, et al.; Jpn. J. Pharmacol. 60, 85 (1992), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Technical Posters
Disease-Associated Stress Signaling
Disease-Associated Stress Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,